skip to Main Content

Ipreo IPO Brief: April 2011

US-listed IPOs raised double the proceeds in April 2011 compared with the prior-year period due to a y/y increase in average deal size. The month saw only one more deal by count compared to the year-ago period, however an 88% boost in average proceeds per IPO helped lift April’s overall figure to nearly $3.8B in capital raised. This trend has been a constant one through the first four months of 2011 with average deal size jumping by 233%, 57%, and 402% y/y, in January, February, and March, respectively. Growth in deal size in 2011 stands in contrast to the prior year when a total of 145 IPOs saw their average deal size decline by 25% y/y.

Ipreo IPO Brief: March 2011

March saw the return of broad market volatility as North Africa and the Middle East slid further into conflict and Japan experienced its devastating earthquake. From 3/1 to 3/16, the VIX Volatility Index jumped 40% while the S&P 500 shed 4%, dropping 2% on 3/16 alone. On the same day, however, the US-based 25 Index actually rose on the back of strong gains from BG Medicine, Inc. (+10%), Endocyte, Inc. (+6%), and MedQuist Holdings Inc. (+6%). While the major indices were locked in a systematic de-risk trade, the US-based 25 Index was able to outperform the major indices and finish the month 3.3% higher.

Ipreo IPO Brief: February 2011

US-listed IPOs accelerated in February as deal volume more than doubled y/y to sixteen from seven. Activity, however, was heavily concentrated in the first half of the month, as only one IPO priced in the last two weeks of February. Total proceeds for the month rose to $4.3B, from the year-ago $1.2B, on the back of Kinder Morgan’s $2.9B offering. Excluding Kinder Morgan, IPOs are trending smaller, with proceeds averaging $93mm compared with $170mm in the year-ago.

Ipreo IPO Brief: January 2011

US-listed IPOs recorded a strong opening to the new year. On a year-over-year basis, eight deals priced to last year’s five as proceeds rose five-fold to $3.9B from $732.6M. While the large Nielsen offering ($1.9B) accounted for the lion’s share of total proceeds, even without the deal, US-domiciled issuance rose 87% from the prior year. Meanwhile, proceeds from international issuers listing in the US rose sharply off a smaller comparable.
Back To Top